(BANGKOK, Sep 12, 2011) Bionor Pharma presented Vacc-4x on “Global HIV Vaccine Enterprise” press conference at AIDS Vaccine 2011 in Bangkok Bionor Pharma was the only company with therapeutic HIV-vaccine having a presentation at Global HIV Vaccine Enterprise (GHVE) press conference, where the aim was to present promising HIV projects. GHVE is a unique alliance of …
Results from Phase IIB Placebo Controlled Study of Bionor’s Vacc-4x Show Excellent Safety Profile and Statistically Significant Viral Load Reduction in Patients with HIV who Suspend Antiretroviral Therapy. Vaccine for People Living with HIV/AIDS Reduces Viral Load. Works by Training Patients’ Immune System to Target the Known “Achilles Heel” of HIV. Could Lead to New …
BioCentury Publications, Inc., a leading provider of value-added information on strategic issues in life science, has in their report BioCentury Week in Review Aug 29, 2011, published the clinical status of the upcoming clinical trial regarding Bionor’s therapeutic vaccine, Vacc-4x in combination with Revlimid®. Link to the reprint